Shoulder Innovations has won FDA 510(k) clearance for the N-22 Humeral Head, a titanium implant built for the estimated 10% to 15% of patients whose bodies react to standard metal shoulder implants. The Grand Rapids, Michigan company announced the clearance on 10 September 2026 alongside an immediate full commercial launch, completing a metal-hypersensitive option across both major forms of shoulder replacement it now sells.
A titanium option where cobalt-chrome causes trouble
Total shoulder replacement implants have conventionally used cobalt-chromium alloy for the humeral head, the ball component that replaces the top of the upper arm bone. Shoulder Innovations says roughly 10% to 15% of the general population tests positive for metal hypersensitivity, and that those patients can experience persistent pain or other allergic-reaction symptoms from a standard metal implant. The N-22 Humeral Head is a titanium alternative sized for anatomic total shoulder arthroplasty — the non-reverse procedure used when a patient’s own rotator cuff is intact — cleared for immediate, full commercial availability rather than a limited release.
“The N-22 Humeral Head augments our line of technologies for patients with metal hypersensitivity, now providing surgeons with a metal-sensitive option across both shoulder arthroplasty configurations.” Rob Ball, Chief Executive Officer, Shoulder Innovations — 10 September 2026 announcement
The N-22 platform, in four numbers
Figures from Shoulder Innovations’ public announcements and SEC filings.
Two clearances, one metal-hypersensitivity answer
From an InSet Glenoid to a full metal-hypersensitive platform
- July 2025
Shoulder Innovations goes public
Prices 5,000,000 shares at $15.00 and begins trading on the NYSE under the ticker SI.
- January 2026
N-22 Glenosphere cleared
FDA 510(k) clearance of a titanium implant for metal-hypersensitive patients in reverse total shoulder arthroplasty.
- Q2 2026
Second-quarter results
Revenue of $17.2 million, up 56% year on year; full-year guidance raised.
- 10 September 2026
N-22 Humeral Head cleared
FDA 510(k) clearance and immediate full commercial launch, extending the metal-hypersensitive option to anatomic shoulder arthroplasty.
- Not yet dated
Next clearance
The company has not disclosed its next 510(k) submission.
What the N-22 platform adds beyond one implant
Both arthroplasty types covered
The N-22 Glenosphere and N-22 Humeral Head together give surgeons a metal-hypersensitive option in both reverse and anatomic total shoulder replacement, rather than just one procedure type.
Built on the InSet Glenoid platform
Shoulder Innovations’ core technology targets glenoid loosening, the company says is the leading complication in anatomic shoulder arthroplasty, and the N-22 implants extend that same platform.
AI-assisted planning bundled in
The company’s ProVoyance preoperative planning software, which it describes as an AI-enabled, CT-based virtual surgery tool, is integrated across its implant lines, including N-22.
A small-cap medtech in a four-company market
Shoulder arthroplasty is a small corner of orthopedics next to hip and knee replacement, but it is a growing one, and it remains dominated by a handful of large, diversified device makers. According to OrthoWorld’s State of Joint Replacement research, four companies — Zimmer Biomet, Stryker, J&J MedTech (DePuy Synthes) and Smith+Nephew — control roughly 71% of worldwide joint-replacement sales, with Enovis and Medacta described as closing the gap. Shoulder Innovations, a pure-play shoulder company that went public in 2025, competes as one of the smaller independents in that field.
Shoulder replacement, two forecasts to the early 2030s
$2.55B → $3.89B
Global shoulder replacement market, 2025 to 2030, per Grand View Research; Market Research Future separately forecasts $2.08B in 2025 rising to $3.26B by 2031.
Sources: Grand View Research, Shoulder Replacement Market Size And Share Report · Market Research Future, Shoulder Replacement Market
Regulatory News outlook
We expect a metal-hypersensitive product line to widen a small-cap challenger’s addressable share of new implant starts more than it grows the overall market, since the underlying patient population — the roughly 10-15% with metal sensitivity — is a subset of demand that already exists.
How we got here: Applying Shoulder Innovations’ own reported revenue growth rate (56% year on year in Q2 2026) against Grand View Research’s $2.55 billion 2025 market base implies the company could roughly double its current market share by 2028 if that growth rate holds, well before the wider market itself is forecast to double.
What full launch means, and what is not yet public
Shoulder Innovations moved directly to full commercial launch rather than a phased or limited release, meaning surgeons can order the N-22 Humeral Head immediately rather than wait for a wider rollout. The company has not disclosed a specific 510(k) clearance number for the device, has not named its next planned submission, and its own release does not break out unit sales expected from the metal-hypersensitive segment specifically.
- Availability: full commercial launch effective 10 September 2026, immediately following clearance.
- Platform: pairs with the N-22 Glenosphere (cleared January 2026) to cover metal-hypersensitive patients in both anatomic and reverse total shoulder arthroplasty.
- Not yet public: the 510(k) K-number, unit or revenue guidance specific to the N-22 Humeral Head, and the company’s next planned FDA submission.
Sources & further reading
- Shoulder Innovations, “Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch,” press release, 10 September 2026. shoulderinnovations.com
- “Shoulder Innovations Granted 510(k) for N-22 Humeral Head,” BONEZONE (ORTHOWORLD), 11 September 2026. bonezonepub.com
- “FDA Clears Shoulder Innovations’ N-22 Humeral Head,” Orthopedic Design & Technology, September 2026. odtmag.com
- Shoulder Innovations investor relations — news releases. ir.shoulderinnovations.com
- Shoulder Innovations, “Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook.” shoulderinnovations.com
- Grand View Research, “Shoulder Replacement Market Size And Share Report.” grandviewresearch.com
- Market Research Future, “Shoulder Replacement Market.” marketresearchfuture.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did FDA clear for Shoulder Innovations?
The N-22 Humeral Head, a titanium implant option for anatomic total shoulder arthroplasty in patients with metal hypersensitivity, cleared 10 September 2026 under a 510(k) with full commercial launch the same day. The specific clearance number (K-number) was not publicly indexed in FDA’s database as of publication.
Who is this implant for?
Shoulder Innovations says roughly 10% to 15% of the general population test positive for metal hypersensitivity and may experience persistent pain or other allergic-reaction symptoms from standard metal shoulder implants. The N-22 Humeral Head offers those patients a titanium alternative in anatomic (non-reverse) shoulder replacement.
How does this relate to the N-22 Glenosphere?
The N-22 Glenosphere, cleared in January 2026, addresses the same metal-hypersensitivity concern in reverse total shoulder arthroplasty. Together, the two clearances give Shoulder Innovations a metal-hypersensitive-patient option across both major shoulder arthroplasty configurations.
Is Shoulder Innovations a public company?
Yes. Shoulder Innovations, Inc. trades on the NYSE under the ticker SI, following an initial public offering that priced 5,000,000 shares at $15.00 each and began trading 31 July 2025.
